Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cytodyn Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12
Venture Financing 14
ProstaGene Raises USD0.4 Million in Financing 14
Cytodyn Raises USD2.7 million in Financing Round 15
CytoDyn Raises USD3.3 million in Venture Financing Round 16
ProstaGene Raises USD0.4 Million in Venture Financing 17
Partnerships 18
CytoDyn Amends Research Agreement with Drexel University College of Medicine 18
Licensing Agreements 19
CytoDyn Enters into Licensing Agreement with Lonza Sales 19
Equity Offering 20
CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20
CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21
CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22
CytoDyn Raises USD1.2 Million in Private Placement of Shares 23
CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24
CytoDyn Raises USD4.3 Million in Private Placement of Shares 25
CytoDyn Raises USD7.3 Million in Private Placement of Shares 26
CytoDyn Completes Final Tranche Of Private Placement Of Units For US$6.7 Million 27
CytoDyn Raises USD14.5 Million in Private Placement of Units 28
CytoDyn Completes Private Placement Of Shares For US$0.6 Million 29
Debt Offering 30
CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30
CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31
CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32
Cytodyn Completes Private Placement Of Notes For US$3.7 Million 33
Acquisition 34
CytoDyn to Acquires ProstaGene 34
Cytodyn Inc – Key Competitors 35
Cytodyn Inc – Key Employees 36
Cytodyn Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Corporate Communications 38
Jan 30, 2017: CytoDyn appoints executive chairman 38
Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 39
Product News 40
12/07/2017: Independent Data Monitoring Committee Recommends Continuation of CytoDyn’s PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary Endpoint 40
08/21/2017: CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 41
08/09/2017: CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial 42
07/12/2018: CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders 43
07/12/2018: CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders 45
06/11/2018: CytoDyn ASM Poster Presentation June 9, 2018, at ASM Microbe 2018, Atlanta, GA 47
06/09/2018: Weekly Injections of CytoDyns PRO 140 in Combination with Optimized Antiretroviral Treatment Shows Long-Acting HIV-1 Viral Suppression 48
06/04/2018: Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9 49
06/01/2017: CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 50
04/11/2018: CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018 51
04/11/2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 52
03/29/2018: CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders 53
02/20/2018: CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection 54
01/30/2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 56
Product Approvals 57
Jun 22, 2018: CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy 57
Mar 14, 2018: CytoDyn to Amend Protocol for PRO 140 Phase 2 Trial in GvHD 58
Oct 13, 2017: CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA 59
Oct 05, 2017: CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease 60
Sep 06, 2017: CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 61
Apr 17, 2017: Potential for CytoDyn’s PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA 62
Jan 11, 2017: CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy 63
Clinical Trials 64
Jul 30, 2018: Cytodyn announces significantly improved response rate at higher dose of PRO 140 in HIV phase 3 monotherapy trial 64
Jul 16, 2018: CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial 66
Jun 26, 2018: New Research Supports Potential for CytoDyn’s PRO 140 to Inhibit Breast Cancer Metastasis 67
Jun 20, 2018: CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD 68
May 24, 2018: Results of CytoDyns PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials 69
Nov 14, 2017: CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation 70
May 17, 2017: CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease 71
Feb 14, 2017: Two-Year Update From CytoDyn’s PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
Cytodyn Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytodyn Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12
ProstaGene Raises USD0.4 Million in Financing 14
Cytodyn Raises USD2.7 million in Financing Round 15
CytoDyn Raises USD3.3 million in Venture Financing Round 16
ProstaGene Raises USD0.4 Million in Venture Financing 17
CytoDyn Amends Research Agreement with Drexel University College of Medicine 18
CytoDyn Enters into Licensing Agreement with Lonza Sales 19
CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20
CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21
CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22
CytoDyn Raises USD1.2 Million in Private Placement of Shares 23
CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24
CytoDyn Raises USD4.3 Million in Private Placement of Shares 25
CytoDyn Raises USD7.3 Million in Private Placement of Shares 26
CytoDyn Completes Final Tranche Of Private Placement Of Units For US$6.7 Million 27
CytoDyn Raises USD14.5 Million in Private Placement of Units 28
CytoDyn Completes Private Placement Of Shares For US$0.6 Million 29
CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30
CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31
CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32
Cytodyn Completes Private Placement Of Notes For US$3.7 Million 33
CytoDyn to Acquires ProstaGene 34
Cytodyn Inc, Key Competitors 35
Cytodyn Inc, Key Employees 36
Cytodyn Inc, Subsidiaries 37
List of Figures
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10